161 related articles for article (PubMed ID: 18559597)
21. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection.
Salonia A; Briganti A; Gallina A; Karakiewicz P; Shariat S; Freschi M; Zanni G; Capitanio U; Bosi E; Rigatti P; Montorsi F
Urology; 2009 Apr; 73(4):850-5. PubMed ID: 19038425
[TBL] [Abstract][Full Text] [Related]
22. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy.
Shariat SF; Menesses-Diaz A; Kim IY; Muramoto M; Wheeler TM; Slawin KM
Urology; 2004 Jun; 63(6):1191-7. PubMed ID: 15183988
[TBL] [Abstract][Full Text] [Related]
23. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
24. Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy.
Fuchsjäger MH; Shukla-Dave A; Hricak H; Wang L; Touijer K; Donohue JF; Eastham JA; Kattan MW
BJU Int; 2009 Aug; 104(3):315-20. PubMed ID: 19220263
[TBL] [Abstract][Full Text] [Related]
25. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
[TBL] [Abstract][Full Text] [Related]
26. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.
George DJ; Regan MM; Oh WK; Tay MH; Manola J; Decalo N; Duggan S; Dewolf WC; Kantoff PW; Bubley GJ
Urology; 2004 Feb; 63(2):327-32. PubMed ID: 14972483
[TBL] [Abstract][Full Text] [Related]
27. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716
[TBL] [Abstract][Full Text] [Related]
28. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer.
Peyromaure M; Badoual C; Camparo P; Grabar S; Goulvestre C; Fulla Y; Vieillefond A; Mao K; Dinh-Xuan AT
Oncol Rep; 2007 Jul; 18(1):145-9. PubMed ID: 17549360
[TBL] [Abstract][Full Text] [Related]
29. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.
Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y
Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359
[TBL] [Abstract][Full Text] [Related]
30. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
Mao K; Badoual C; Camparo P; Delongchamps NB; Vieillefond A; Dinh-Xuan AT; Peyromaure M
Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815
[TBL] [Abstract][Full Text] [Related]
31. Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era.
Mann MJ; DeCastro GJ; Desai M; Benson MC; McKiernan JM
Urology; 2008 Dec; 72(6):1203-7. PubMed ID: 18674807
[TBL] [Abstract][Full Text] [Related]
32. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer.
Karam JA; Svatek RS; Karakiewicz PI; Gallina A; Roehrborn CG; Slawin KM; Shariat SF
Clin Cancer Res; 2008 Mar; 14(5):1418-22. PubMed ID: 18316564
[TBL] [Abstract][Full Text] [Related]
33. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of nodal metastases in prostate cancer patients at high risk for lymph node involvement.
Isebaert S; Haustermans K; Van den Bergh L; Joniau S; Dirix P; Oyen R; Deroose CM; Van Poppel H; Lerut E
Acta Oncol; 2013 Oct; 52(7):1336-44. PubMed ID: 23879650
[TBL] [Abstract][Full Text] [Related]
36. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
[TBL] [Abstract][Full Text] [Related]
37. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT
BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444
[TBL] [Abstract][Full Text] [Related]
38. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.
Lane BR; Stephenson AJ; Magi-Galluzzi C; Lakin MM; Klein EA
Urology; 2008 Dec; 72(6):1240-5. PubMed ID: 18692874
[TBL] [Abstract][Full Text] [Related]
39. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
[TBL] [Abstract][Full Text] [Related]
40. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
